Number of patients | Patient characteristics | CIAKI incidence, % | Marker capture time, h | Conclusion | Statistics | Authors |
100 | GFR > 60 ml, Age 63.2 ± 12.0 yrs. | 11% | 0, 2, 4, 8, 24 | Significant NGAL increase in 2 hours | Serum NGAL increase in 2 hours (p < 0.05), in 4 h (p < 0.01), in 8 hours (p < 0.05), urine NGAL increase in 4 hours (p < 0.05), in 8 hours (p < 0.001), in 12 hours (p < 0.05) | [45] |
140 | DM/non-DM, GFR > 60 ml, Age 63.8 ± 11.4 yrs. | 14% (DM) 10% (non-DM) | 0, 2, 4, 8, 24 | Significant NGAL increase in both cohorts, more significant in DM cohort | p < 0.05 for both cohorts vs marker level before CM administration, p < 0.001 for DM vs non-DM cohort | [46] |
25 | non-DM, GFR > 60 ml, Age 64.3 ± 9.8 yrs. | 0% | 0, 2, 4, 12 | No CIAKI. Significant NGAL increase in 2 hours | Serum NGAL increase in 2 hours (p < 0.05), in 4 hours (p < 0.01), urine NGAL increase in 4 and 12 hours (p < 0.05) | [47] |
150 | GFR > 60 ml, Age 66.3 ± 9.9 yrs. | 8.7% | 0.24 | Significant NGAL increase during first 24 hours | p < 0.05 vs. control group | [48] |
208 | DM + GFR > 60 ml, Age 70.8 ± 8.5 yrs. | 18.8% | 0, 2, 4, 12 - 24 | Significant NGAL increase already in 2 hours | p = 0.03 (2 hours), p = 0.007 (4 hours), p = 0.0015 (12 - 24 hours) | [49] |